Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist

Código QR

Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist

Adoptive cell transfer (ACT) of T cells for tumor treatment often requires IL-2 administration. Here, the authors show that a modified IL-2 cytokine (NKTR-214) can outperform IL-2 in a melanoma mouse model.

Guardado en:

Detalles Bibliográficos
Autores principales:	Giulia Parisi, Justin D. Saco, Felix B. Salazar, Jennifer Tsoi, Paige Krystofinski, Cristina Puig-Saus, Ruixue Zhang, Jing Zhou, Gardenia C. Cheung-Lau, Alejandro J. Garcia, Catherine S. Grasso, Richard Tavaré, Siwen Hu-Lieskovan, Sean Mackay, Jonathan Zalevsky, Chantale Bernatchez, Adi Diab, Anna M. Wu, Begoña Comin-Anduix, Deborah Charych, Antoni Ribas
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2020
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/26da1a14c88d4cdbbb1ebbe52eeb9731
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Descripción
Sumario:	Adoptive cell transfer (ACT) of T cells for tumor treatment often requires IL-2 administration. Here, the authors show that a modified IL-2 cytokine (NKTR-214) can outperform IL-2 in a melanoma mouse model.